European Commission Approves KEYTRUDA®(pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Brightstar Lottery PLC Announces Posting of Notice of 2026 Annual General Meeting and 2025 Annual Report and Accounts
Lindsay Corporation Reports Fiscal 2026 Second Quarter Results
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Sally Beauty Holdings Appoints Adrianne Lee as Chief Financial Officer
Sonic Automotive Schedules Release of First Quarter and 2026 Financial Results
Scorpio Tankers Inc. Announces Strategic Collaboration with AMPERA, Inc. to Develop & Commercialize Micronuclear Solutions for Global Marine and Shipping Markets